LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker

Nature Medicine

Volumn 18, Issue 10, 2012, Pages 1511-1517

  Chen, Dahu ^a   Sun, Yutong ^a   Wei, Yongkun ^a   Zhang, Peijing ^a   Rezaeian, Abdol Hossein ^a   Teruya Feldstein, Julie ^b   Gupta, Sumeet ^c   Liang, Han ^a   Lin, Hui Kuan ^a,d   Hung, Mien Chie ^a,d,e   Ma, Li ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HIPPO KINASE; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MICRORNA 9; PHOSPHOTRANSFERASE; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CONTROLLED STUDY; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870261155     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2940     Document Type: Article

References (42)

1. Lee, Y.T. Breast carcinoma: pattern of metastasis at autopsy. J. Surg. Oncol. 23, 175-180 (1983).
2. Weigelt, B., Peterse, J.L. & van 't Veer, L.J. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591-602 (2005).
3. Steeg, P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12, 895-904 (2006).
4. Steeg, P.S. & Theodorescu, D. Metastasis: a therapeutic target for cancer. Nat. Clin. Pract. Oncol. 5, 206-219 (2008).
5. Vaidya, K.S. & Welch, D.R. Metastasis suppressors and their roles in breast carcinoma. J. Mammary Gland Biol. Neoplasia 12, 175-190 (2007).
6. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
7. He, L. & Hannon, G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531 (2004).
8. Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
9. Nicoloso, M.S., Spizzo, R., Shimizu, M., Rossi, S. & Calin, G.A. MicroRNAs\the micro steering wheel of tumour metastases. Nat. Rev. Cancer 9, 293-302 (2009).
10. Ma, L., Teruya-Feldstein, J. & Weinberg, R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682-688 (2007).
11. Tavazoie, S.F. et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152 (2008).
12. Huang, Q. et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 10, 202-210 (2008).
13. Valastyan, S. et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032-1046 (2009).
14. Ma, L. et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12, 247-256 (2010).
15. Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341-347 (2010).
16. Huntsman, D.G. et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N. Engl. J. Med. 344, 1904-1909 (2001).
17. Chan, J.K. & Wong, C.S. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infltrating lobular carcinoma of the breast. Adv. Anat. Pathol. 8, 165-172 (2001).
18. Lewis, B.P., Burge, C.B. & Bartel, D.P. Conserved seed pairing, often fanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 (2005).
19. Gearing, D.P. The leukemia inhibitory factor and its receptor. Adv. Immunol. 53, 31-58 (1993).
20. Kishimoto, T., Akira, S., Narazaki, M. & Taga, T. Interleukin-6 family of cytokines and gp130. Blood 86, 1243-1254 (1995).
21. Tamm, C., Bower, N. & Anneren, C. Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. J. Cell Sci. 124, 1136-1144 (2011).
22. Zhao, B. et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25, 51-63 (2011).
23. Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761 (2007).
24. Zhao, B. et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22, 1962-1971 (2008).
25. Zhao, B., Li, L., Lei, Q. & Guan, K.L. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 24, 862-874 (2010).
26. Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 19, 491-505 (2010).
27. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
28. Dong, J. et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120-1133 (2007).
29. Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759-772 (2011).
30. Rhodes, D.R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6 (2004).
31. Richardson, A.L. et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121-132 (2006).
32. Zhao, H. et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell 15, 2523-2536 (2004).
33. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527 (2008).
34. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874 (2001).
35. Radvanyi, L. et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc. Natl. Acad. Sci. USA 102, 11005-11010 (2005).
36. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418-8423 (2003).
37. Turashvili, G. et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7, 55 (2007).
38. Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
39. Karnoub, A.E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563 (2007).
40. Smith, S.C. & Theodorescu, D. Learning therapeutic lessons from metastasis suppressor proteins. Nat. Rev. Cancer 9, 253-264 (2009).
41. Stewart, S.A. et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493-501 (2003).
42. Rehmsmeier, M., Steffen, P., Hochsmann, M. & Giegerich, R. Fast and effective prediction of microRNA/target duplexes. RNA 10, 1507-1517 (2004).